Patrick Henning to lead CLSA’s Federal, State and Local Government Relations, Communications, Policy and Alliance Development Efforts on behalf of California’s life sciences sector
House overwhelmingly passes year-end spending deal that includes a permanent repeal of the 2.3% medical device tax, Senate likely to approve
On Dec. 12, the U.S. House is set to vote on H.R. 3, a bill that will have catastrophic consequences for patients and California’s life sciences sector. Learn why in this STAT News op-ed from CLSA CEO Mike Guerra.
CLSA President & CEO Mike Guerra pens an op-ed in the San Francisco Chronicle on the urgency and need for Congress to repeal the medical device tax.
On November 18, 2019, as a result of the advocacy of CLSA’s Washington, D.C. based team and the leadership of Congressman Lou Correa (D-Santa Ana), a California Democratic Delegation letter was sent to House Leadership urging swift action to repeal the medical device tax before the end of the year.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, today announced the expansion of its board of directors, adding three new members. Joining the board are: Mohit Trikha, Ph.D., Vice President, Head of Oncology Early Development & AbbVie Bay Area Site Head; Lesley Stolz, Ph.D., Managing Director, Lasana Partners; and Grace Han McMahon, Head of Transactions, Pacific Innovation Hub, Business Development & Licensing, Merck Research Laboratories.
CLSA’s HR 3 impact study was featured in this high-profile STAT News article, highlighting the impact that the drug pricing proposal (HR 3) would have on small and emerging biotechnology companies in California.
California Life Sciences Association was recently featured in the San Diego Union-Tribune regarding its new study on the impact of international reference pricing. Up to 88 percent fewer new drug approvals projected in study commissioned by Biocom and California Life Sciences Association.